Complete report $1,950. Individual company assessments $250. The companies analyzed in this report include Bayer, Boehringer Ingelhein, Ceva, Elanco, Intervet, Merial, Novartis, Pfizer, Phibro, and Virbac. For each company, the report provides: • Specific business, new product development and marketing strategies. • Anticipated acquisitions, joint ventures and divestitures. • Major strengths and weaknesses. Contains 30 pages
|